Human VHL protein
Recombinant protein from the full-length sequence of homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1 (NM_000551), with a DYKDDDDK tag.
HRCA1; pVHL; RCA1; VHL1
>90% by SDS-PAGE gel and Coomassie Blue staining
Antigens, Western, ELISA and other in vitro binding or in vivo functional assays, and protein-protein interaction studies; For research & development use only!
Purified protein formulated in a sterile solution of TBS buffer, pH7.4, without any preservatives
Endotoxin level is < 0.1 ng/µg of protein (<1EU /µg)
Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. A germline mutation of this gene is the basis of familial inheritance of VHL syndrome. The protein encoded by this gene is a component of the protein complex that includes elongin B, elongin C, and cullin-2, and possesses ubiquitin ligase E3 activity. This protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. RNA polymerase II subunit POLR2G/RPB7 is also reported to be a target of this protein. Alternatively spliced transcript variants encoding distinct isoforms have been observed. [provided by RefSeq, Jul 2008].
Fig 1 : SDS-Page Image
There's no citations at this moment.
There's no FAQs at this moment.
There's no reviews at this moment.